×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Virology Specimen Collection Market

ID: MRFR/HC/9314-HCR
120 Pages
Rahul Gotadki
October 2025

Virology Specimen Collection Market Size, Growth Research Report By Product Type (Swabs, Viral Transport Media, Blood Collection Kits, and Others), By Application (Diagnostics and Research), By End User (Hospitals & Clinics, Diagnostic Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Competitor Industry Analysis and Trends Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Virology Specimen Collection Market Infographic
×
Virology Specimen Collection Market Infographic Full View
Purchase Options

Virology Specimen Collection Market Summary

As per MRFR analysis, the Virology Specimen Collection Market Size was estimated at 6.42 USD Billion in 2024. The Virology Specimen Collection industry is projected to grow from 6.76 USD Billion in 2025 to 11.34 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.3 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Virology Specimen Collection Market is experiencing robust growth driven by technological advancements and increasing healthcare investments.

  • Technological advancements in collection devices are enhancing the efficiency and accuracy of specimen collection processes.
  • North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for virology specimen collection.
  • The diagnostic testing segment dominates the market, whereas the vaccine development segment is witnessing rapid growth.
  • Rising incidence of viral infections and increased investment in healthcare infrastructure are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 6.42 (USD Billion)
2035 Market Size 11.34 (USD Billion)
CAGR (2025 - 2035) 5.3%

Major Players

Thermo Fisher Scientific (US), BD (US), Roche Diagnostics (CH), Abbott Laboratories (US), Qiagen (DE), PerkinElmer (US), Hologic (US), Meridian Bioscience (US), Bio-Rad Laboratories (US)

Virology Specimen Collection Market Trends

The Virology Specimen Collection Market is currently experiencing a notable evolution, driven by advancements in diagnostic technologies and an increasing emphasis on infectious disease management. The demand for efficient and reliable specimen collection methods is rising, as healthcare providers seek to enhance patient outcomes and streamline laboratory processes. Innovations in collection devices, such as swabs and vials, are being developed to ensure optimal specimen integrity and ease of use. Furthermore, the growing awareness of viral infections and the need for rapid testing solutions are propelling market growth, as stakeholders aim to improve public health responses and surveillance systems. In addition, regulatory bodies are playing a crucial role in shaping the landscape of the Virology Specimen Collection Market. Stringent guidelines and standards are being established to ensure the safety and efficacy of collection methods. This regulatory environment encourages manufacturers to invest in research and development, fostering a competitive atmosphere that may lead to the introduction of novel products. As the market continues to evolve, collaboration among healthcare professionals, researchers, and manufacturers appears essential to address emerging challenges and meet the increasing demand for effective specimen collection solutions.

Technological Advancements in Collection Devices

The Virology Specimen Collection Market is witnessing a surge in technological innovations aimed at enhancing the efficiency and reliability of specimen collection. New materials and designs are being introduced to improve the performance of collection devices, ensuring that specimens are preserved in optimal conditions. This trend reflects a broader movement towards integrating technology into healthcare practices, which may lead to better diagnostic outcomes.

Increased Focus on Infectious Disease Management

There is a growing emphasis on infectious disease management within the Virology Specimen Collection Market. As healthcare systems prioritize the prevention and control of viral infections, the demand for effective specimen collection methods is likely to rise. This trend suggests a shift towards proactive healthcare strategies, where timely and accurate specimen collection plays a pivotal role in managing public health.

Regulatory Influence on Market Dynamics

Regulatory bodies are increasingly influencing the Virology Specimen Collection Market by establishing stringent guidelines for specimen collection practices. These regulations aim to ensure safety and efficacy, prompting manufacturers to innovate and comply with evolving standards. This trend indicates a dynamic market environment where adherence to regulations is essential for success.

Virology Specimen Collection Market Drivers

Market Growth Projections

The Global Virology Specimen Collection Market Industry is projected to experience substantial growth over the next decade. With a market value anticipated to reach 6.42 USD Billion in 2024 and further escalate to 11.3 USD Billion by 2035, the industry is poised for a robust expansion. The compound annual growth rate (CAGR) of 5.31% from 2025 to 2035 indicates a sustained upward trajectory, driven by factors such as technological advancements, increased demand for testing, and enhanced government support. This growth reflects the critical role of specimen collection in addressing global health challenges and improving disease management.

Growing Focus on Personalized Medicine

The shift towards personalized medicine is influencing the Global Virology Specimen Collection Market Industry, as healthcare providers seek tailored treatment approaches based on individual patient profiles. This trend necessitates precise specimen collection methods to ensure accurate diagnostics and treatment plans. As healthcare systems increasingly adopt personalized strategies, the demand for high-quality specimens is expected to rise. This evolution in medical practice underscores the importance of reliable specimen collection, which is essential for the successful implementation of personalized therapies. Consequently, this focus on individualized care may drive market expansion in the coming years.

Increased Government Initiatives and Funding

Government initiatives aimed at improving public health infrastructure are significantly impacting the Global Virology Specimen Collection Market Industry. Increased funding for virology research and specimen collection programs is being observed globally, as governments recognize the importance of preparedness against viral outbreaks. This financial support facilitates the development of better collection protocols and training for healthcare professionals. Furthermore, public health campaigns are raising awareness about the importance of specimen collection in disease management. Such initiatives are likely to bolster market growth, as they enhance the capacity for effective viral surveillance and response.

Rising Demand for Infectious Disease Testing

The Global Virology Specimen Collection Market Industry is experiencing heightened demand for infectious disease testing, driven by the increasing prevalence of viral infections. As healthcare systems worldwide prioritize early detection and diagnosis, the market is projected to reach 6.42 USD Billion in 2024. This surge is indicative of a broader trend towards proactive healthcare measures, where timely specimen collection plays a crucial role in managing outbreaks and ensuring public health safety. Enhanced awareness among populations regarding viral diseases further fuels this demand, suggesting a sustained growth trajectory for the industry.

Emerging Markets and Global Health Initiatives

Emerging markets are playing a pivotal role in the Global Virology Specimen Collection Market Industry, as global health initiatives aim to enhance disease surveillance and response capabilities. Countries in regions such as Africa and Southeast Asia are receiving increased attention due to their vulnerability to viral outbreaks. International collaborations and funding are being directed towards improving specimen collection infrastructure in these areas, which is crucial for effective disease monitoring. As these markets develop their healthcare systems, the demand for virology specimen collection is likely to grow, contributing to the overall expansion of the industry.

Technological Advancements in Collection Methods

Technological innovations are transforming the Global Virology Specimen Collection Market Industry, with advancements in collection methods enhancing efficiency and accuracy. Novel devices and automated systems are being developed to streamline specimen collection processes, thereby reducing the risk of contamination and improving sample integrity. For instance, the introduction of self-collection kits has empowered patients to participate in their own healthcare, potentially increasing testing rates. As these technologies continue to evolve, they are likely to contribute to the market's growth, which is expected to reach 11.3 USD Billion by 2035, reflecting a robust CAGR of 5.31% from 2025 to 2035.

Market Segment Insights

By Application: Diagnostic Testing (Largest) vs. Vaccine Development (Fastest-Growing)

The Virology Specimen Collection Market is primarily driven by several key applications. Diagnostic Testing leads this segment, reflecting a robust market demand due to the increasing prevalence of viral infections and the need for rapid testing solutions. Following closely are Research and Development, Blood Screening, and Vaccine Development, with the latter experiencing significant growth as vaccine innovation ramps up in response to emerging viral threats.

Diagnostic Testing (Dominant) vs. Vaccine Development (Emerging)

Diagnostic Testing is a critical component of the Virology Specimen Collection Market, serving as the primary method for identifying viral infections across diverse populations. This segment benefits from advanced testing technologies and heightened awareness of viral diseases, particularly in the wake of global pandemics. In contrast, Vaccine Development is emerging as an increasingly pivotal area, driven by the growing investments in research and a demand for rapid responses to viral outbreaks. This segment is characterized by extensive collaboration between public and private sectors, leveraging cutting-edge technologies to expedite vaccine rollout.

By Type of Specimen: Blood Samples (Largest) vs. Nasal Swabs (Fastest-Growing)

In the Virology Specimen Collection Market, Blood Samples hold the largest share due to their reliability and widespread acceptance in diagnostic testing. They are often preferred for various viral tests, providing a comprehensive analysis of viral load and presence. While Blood Samples lead in terms of market share, Nasal Swabs have emerged as a prominent choice owing to their ease of collection and non-invasive nature, which is increasingly appealing in clinical settings. The growth trends for the segment reveal a significant shift towards convenience and patient comfort, with Nasal Swabs experiencing rapid adoption. This method is being driven by the increasing prevalence of viral infections, advances in testing technology, and greater awareness about respiratory diseases. As healthcare providers seek to streamline testing processes, the demand for Nasal Swabs is expected to continue its upward trajectory, marking it as the fastest-growing segment in the market.

Blood Samples (Dominant) vs. Throat Swabs (Emerging)

In the Virology Specimen Collection Market, Blood Samples are recognized as the dominant specimen type due to their extensive usage in detecting a wide array of viral infections and their proven effectiveness in clinical diagnostics. The established protocols for blood testing, coupled with their ability to provide quantifiable results, reinforce their strong position in the market. Throat Swabs, on the other hand, are considered an emerging segment due to their growing acceptance in viral diagnostics, particularly in identifying respiratory viruses. While still developing in terms of widespread clinical adoption, Throat Swabs offer a less invasive alternative to Blood Samples, appealing to both patients and healthcare professionals. As methodologies for throat swab collection and analysis improve, this segment is poised for growth.

By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Virology Specimen Collection Market, the distribution of market share among end users indicates a clear dominance of hospitals, which hold a significant portion of the overall market. Their extensive infrastructure and the need for regular testing and specimen collection contribute to their leading position. Following closely, diagnostic laboratories are also prominent, leveraging advanced technologies to enhance testing capabilities and efficiency, thereby securing a noteworthy share in the market.

End Users: Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals are the dominant end users in the Virology Specimen Collection Market due to their critical role in patient care and disease management. They exhibit a robust infrastructure that supports high volumes of specimen collection and processing, aided by well-trained personnel. On the other hand, research institutions are emerging players that focus on innovative research and development for virology studies. This segment is characterized by growing investments in research activities and collaborations with pharmaceuticals, enabling them to explore novel methodologies for specimen collection which enhances their position in the market.

Get more detailed insights about Virology Specimen Collection Market

Regional Insights

North America : Market Leader in Virology

North America is poised to maintain its leadership in the Virology Specimen Collection Market, holding a significant market share of 3.5 billion in 2024. The region's growth is driven by increasing healthcare expenditure, advancements in diagnostic technologies, and a robust regulatory framework that supports innovation. The rising prevalence of viral infections and the demand for efficient specimen collection methods further fuel market expansion. The United States stands out as the leading country, hosting major players like Thermo Fisher Scientific, BD, and Abbott Laboratories. The competitive landscape is characterized by continuous innovation and strategic partnerships among key players. The presence of advanced healthcare infrastructure and a focus on research and development contribute to the region's dominance in the global market.

Europe : Emerging Market Dynamics

Europe's Virology Specimen Collection Market is projected to grow, with a market size of 1.8 billion. Key growth drivers include increasing awareness of viral diseases, supportive government initiatives, and advancements in healthcare technologies. The region benefits from stringent regulatory standards that ensure high-quality specimen collection, which is crucial for accurate diagnostics and treatment. Leading countries such as Germany, France, and the UK are at the forefront of this market, with significant contributions from companies like Roche Diagnostics and Qiagen. The competitive landscape is marked by innovation and collaboration among industry players, enhancing the region's capability to address emerging health challenges. The European market is expected to see continued investment in research and development to improve specimen collection methods.

Asia-Pacific : Rapid Growth Potential

The Asia-Pacific region is witnessing rapid growth in the Virology Specimen Collection Market, with a market size of 1.5 billion. Factors driving this growth include increasing healthcare investments, rising awareness of viral infections, and a growing population. The region's diverse healthcare landscape and improving access to diagnostic services are also significant contributors to market expansion. Countries like China, India, and Japan are leading the charge, with a mix of local and international players such as PerkinElmer and Hologic. The competitive environment is evolving, with a focus on enhancing product offerings and expanding distribution networks. As the region continues to develop its healthcare infrastructure, the demand for efficient specimen collection solutions is expected to rise significantly.

Middle East and Africa : Developing Market Landscape

The Middle East and Africa region is gradually emerging in the Virology Specimen Collection Market, with a market size of 0.62 billion. Key growth drivers include increasing healthcare investments, rising incidences of viral diseases, and government initiatives aimed at improving healthcare infrastructure. The region's diverse demographics and varying healthcare needs present both challenges and opportunities for market players. Countries like South Africa and the UAE are leading the market, with a growing presence of international companies. The competitive landscape is characterized by a mix of local and The Virology Specimen Collection share. As healthcare systems evolve, the demand for reliable specimen collection methods is expected to grow, paving the way for future investments in this sector.

Virology Specimen Collection Market Regional Image

Key Players and Competitive Insights

The Virology Specimen Collection Market is currently characterized by a dynamic competitive landscape, driven by the increasing demand for efficient and reliable specimen collection methods. Key players such as Thermo Fisher Scientific (US), BD (US), and Roche Diagnostics (CH) are strategically positioned to leverage their extensive product portfolios and technological advancements. These companies are focusing on innovation and partnerships to enhance their market presence. For instance, Thermo Fisher Scientific (US) has been investing in R&D to develop next-generation specimen collection devices, which could potentially improve diagnostic accuracy and patient outcomes. This collective emphasis on innovation and strategic collaborations among major players is shaping a competitive environment that prioritizes quality and efficiency.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears to be moderately fragmented, with several players vying for market share. However, the influence of key players like Abbott Laboratories (US) and Qiagen (DE) is notable, as they continue to expand their global footprint through strategic acquisitions and partnerships. This competitive structure suggests that while there is room for smaller players, the dominance of established companies is likely to shape market trends and consumer preferences.

In November BD (US) announced a strategic partnership with a leading telehealth provider to integrate specimen collection services into remote patient monitoring systems. This move is significant as it aligns with the growing trend of digital health solutions, potentially enhancing patient access to testing and improving overall healthcare delivery. By leveraging telehealth capabilities, BD (US) is likely to strengthen its market position and cater to the evolving needs of healthcare providers and patients alike.

In October Roche Diagnostics (CH) launched a new line of automated specimen collection systems designed to streamline laboratory workflows. This innovation is crucial as it addresses the increasing demand for efficiency in laboratory operations, particularly in high-throughput environments. The introduction of such advanced systems may not only enhance Roche's competitive edge but also set new standards for operational excellence in the industry.

In September Abbott Laboratories (US) expanded its product offerings by acquiring a startup specializing in mobile specimen collection technologies. This acquisition is indicative of Abbott's commitment to innovation and its strategy to diversify its portfolio. By integrating mobile solutions, Abbott is likely to enhance patient convenience and accessibility, which could be a key differentiator in the market.

As of December current competitive trends in the Virology Specimen Collection Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a pivotal role in shaping the landscape, as companies seek to combine resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative solutions that meet the changing demands of healthcare providers and patients.

Key Companies in the Virology Specimen Collection Market include

Industry Developments

  • Q2 2024: BD Launches New Swab Collection System for Viral Diagnostics BD announced the launch of its new BD ESwab™ 2.0 Collection and Transport System, designed to improve the stability and recovery of viral specimens for diagnostic testing, expanding its virology specimen collection portfolio.
  • Q1 2024: Thermo Fisher Scientific Expands Viral Transport Media Production Facility in North Carolina Thermo Fisher Scientific opened a new production line at its North Carolina facility to increase output of viral transport media, supporting global demand for virology specimen collection products.
  • Q2 2024: Roche Receives CE Mark for New Cobas PCR Media Dual Swab Kit Roche announced it has received CE Mark approval for its Cobas PCR Media Dual Swab Kit, enabling more efficient collection and transport of virology specimens for molecular testing in Europe.
  • Q3 2024: QIAGEN Launches QIAstat-Dx Viral Panel with Enhanced Specimen Collection Kit QIAGEN introduced an upgraded QIAstat-Dx Viral Panel, featuring a new specimen collection kit designed to improve sample integrity and workflow for virology diagnostics.
  • Q2 2024: FDA Authorizes New Self-Collection Swab for At-Home Viral Testing The FDA granted Emergency Use Authorization to a new self-collection swab device for at-home collection of virology specimens, expanding access to diagnostic testing.
  • Q1 2024: Puritan Medical Products Announces $25 Million Expansion for Swab Manufacturing Puritan Medical Products announced a $25 million investment to expand its manufacturing capacity for viral specimen collection swabs at its Maine facility.
  • Q2 2024: Copan Diagnostics Partners with NHS to Supply Virology Collection Kits Copan Diagnostics entered a partnership with the UK National Health Service to supply advanced virology specimen collection kits for use in public health laboratories.
  • Q3 2024: Greiner Bio-One Launches New Saliva Collection Device for Viral Testing Greiner Bio-One launched a new saliva collection device aimed at improving the ease and accuracy of virology specimen collection for both clinical and research applications.
  • Q2 2024: Roche Acquires Minority Stake in SwabTech, a Virology Collection Device Startup Roche announced the acquisition of a minority stake in SwabTech, a startup specializing in innovative virology specimen collection devices, to accelerate product development.
  • Q1 2025: Thermo Fisher Scientific Appoints New VP of Global Specimen Collection Business Thermo Fisher Scientific named Dr. Lisa Chen as Vice President of its Global Specimen Collection Business, overseeing strategy and operations for virology specimen collection products.
  • Q2 2025: BD Receives FDA Clearance for Next-Generation Viral Transport Medium BD received FDA clearance for its next-generation viral transport medium, designed to enhance the stability and safety of virology specimen collection and transport.
  • Q2 2024: Copan Diagnostics Opens New European Distribution Center Copan Diagnostics opened a new distribution center in the Netherlands to streamline delivery of virology specimen collection kits across Europe.
.webp

Future Outlook

Virology Specimen Collection Market Future Outlook

The Virology Specimen Collection Market is projected to grow at a 5.3% CAGR from 2024 to 2035, driven by technological advancements, increasing demand for diagnostics, and enhanced healthcare infrastructure.

New opportunities lie in:

  • Development of mobile specimen collection units for remote areas.
  • Integration of AI-driven analytics for specimen processing efficiency.
  • Expansion of partnerships with telehealth platforms for specimen collection services.

By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

Market Segmentation

Virology Specimen Collection Market End User Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Blood Banks

Virology Specimen Collection Market Application Outlook

  • Diagnostic Testing
  • Research and Development
  • Blood Screening
  • Vaccine Development

Virology Specimen Collection Market Type of Specimen Outlook

  • Blood Samples
  • Saliva Samples
  • Nasal Swabs
  • Throat Swabs

Report Scope

MARKET SIZE 20246.42(USD Billion)
MARKET SIZE 20256.76(USD Billion)
MARKET SIZE 203511.34(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)5.3% (2025 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledThermo Fisher Scientific (US), BD (US), Roche Diagnostics (CH), Abbott Laboratories (US), Qiagen (DE), PerkinElmer (US), Hologic (US), Meridian Bioscience (US), Bio-Rad Laboratories (US)
Segments CoveredApplication, Type of Specimen, End User
Key Market OpportunitiesIntegration of advanced automation technologies enhances efficiency in the Virology Specimen Collection Market.
Key Market DynamicsTechnological advancements and regulatory changes drive innovation in virology specimen collection methodologies and practices.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What is the projected growth of the Virology Specimen Collection market?

The Virology Specimen Collection market is the expected increase in total market value of 11.34 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Virology Specimen Collection market?

Virology Specimen Collection market size was valued at approximately 6.42 billion USD in 2024. This figure will reach 11.34 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Virology Specimen Collection market?

Virology Specimen Collection market is expected to grow at a CAGR of 5.3% between 2025 and 2035.

How much will the Virology Specimen Collection market be worth by 2035?

Virology Specimen Collection market is expected to be worth of 11.34 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Virology Specimen Collection market perform over the next 10 years?

Over the next 10 years the Virology Specimen Collection market is expected to shift from usd billion 6.42 to 11.34 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions